Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

GSK690 is a lysine-specific demethylase 1 (LSD1) inhibitor (IC50 = 0.09 µM in a cell-free assay).1 It is selective for LSD1 over monoamine oxidase A (MAO-A; IC50 = >200 µM). GSK690 inhibits LSD1 activity in THP-1 acute myeloid leukemia cells (IC50 = 1.4 µM). GSK690 potentiates reductions in viability of SJCRH30 rhabdomyosarcoma cells induced by the histone deacetylase (HDAC) inhibitor JNJ-26481585 (Item No. 14088).2
WARNING This product is not for human or veterinary use.
1. Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments. MedChemComm 4, 1513 (2013).
2. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells. Cell Death Dis. 8(6), e2879 (2017).